Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network Inc (NYSE: BFLY) pioneers accessible medical imaging solutions through its revolutionary Ultrasound-on-Chip™ technology. This dedicated news hub provides investors and healthcare professionals with essential updates on product innovations, financial developments, and strategic initiatives driving the future of point-of-care diagnostics.
Discover official press releases covering earnings announcements, regulatory milestones, and partnerships advancing AI-powered ultrasound technology. Our curated collection ensures timely access to verified information about BFLY's handheld imaging systems, educational programs, and market expansion efforts.
Key updates include product launch details, clinical validation studies, and executive leadership changes. Bookmark this page to monitor how Butterfly Network's cloud-connected devices and ScanLab™ training tools continue transforming medical imaging accessibility worldwide.
Butterfly Network has launched its first specialty product, iQ+ Bladder, aimed at the bladder scanning market in the United States.
This product expands Butterfly's reach beyond its core point-of-care ultrasound market, leveraging its proprietary Ultrasound-on-Chip™ technology. The bundled solution includes an iQ+ Bladder probe, streamlined software, a compact rolling cart, a tablet, and a power splitter.
The iQ+ Bladder enables nurses to obtain automated bladder volume calculations with 3D visualizations swiftly. The user-friendly interface, robust design, and advanced visualization capabilities make it a valuable tool in today's healthcare environment, targeting efficiency, reliability, and workflow optimization. The product is designed to meet the needs of nurses and other providers who conduct regular bladder scans.
Butterfly Network, Inc. (NYSE: BFLY) reported a 14% revenue growth in the first quarter of 2024, exceeding expectations. The company achieved record revenue of $17.7 million, reduced net loss by 35%, and net cash used in operations by 52%. They successfully launched the Butterfly iQ3™ and ScanLab™ training app, received EU MDR certification, and announced plans to expand into the European market. Butterfly Network's recent operational highlights include FDA clearance for the Butterfly iQ3™, EU MDR certification for the Butterfly iQ+, and the launch of ScanLab™. The company's gross profit was $10.3 million, with a gross margin of 58.2%. Operating expenses decreased by 25% to $32.9 million, resulting in a net loss of $21.8 million. Adjusted EBITDA loss was $13.2 million. Butterfly Network raised its full year guidance for 2024 to $75-80 million in revenue, with an adjusted EBITDA loss of $55-50 million.
FAQ
What is the current stock price of Butterfly Network (BFLY)?
What is the market cap of Butterfly Network (BFLY)?
